3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Tumor-Agnostic
3
Lymphoid
3
Genitourinary
3
Thoracic
2
Other hematologic neoplasm
2
Gastrointestinal
2
Endocrine
2
CNS
2
Sarcoma
1
NET
1
Head & Neck
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Neoplasm Metastasis
4
Neoplasms
3
Neoplasms, Unknown Primary
1
Interventions
Surveys and Questionnaires
65
pembrolizumab
56
Gemcitabine
54
Paclitaxel
51
Blood Specimen Collection
45
Carboplatin
44
Bevacizumab
41
Docetaxel
38
Cisplatin
33
Nivolumab
32
Fluorouracil
31
Capecitabine
28
Radiotherapy
25
Pemetrexed
25
Irinotecan
25
Standard of Care
24
Interviews as Topic
24
Magnetic Resonance Spectroscopy
23
Leucovorin
22
Erlotinib Hydrochloride
22
atezolizumab
21
Cetuximab
21
Afatinib
21
Oxaliplatin
19
trametinib
18
Exercise
18
Ipilimumab
17
Sorafenib
16
Cyclophosphamide
16
olaparib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasms
×
alectinib
×
Tumor-Agnostic
×
Clear all
NCT03768063
2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3
Active not recruiting
1,000 enrolled
NCT04341181
2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2
Recruiting
300 enrolled
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled